Key facts
- DesiCorp’s last known valuation is $30.1M (Apr 2026).
- It has raised $6.0M across 2 recorded rounds; the latest was Seed Round ($3.5M) in Mar 2026.
- Notable investors include US National Science Foundation, United States Department of War, National Institutes of Health, Keyhorse Capital, Kentucky Innovation Network — 8 tracked in total.
- DesiCorp has filed 2 Form Ds with the SEC since 2024, most recently Nov 2025 ($4.2M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for DesiCorp
Funding rounds
2 roundsAbout DesiCorp
Developer of a freeze-dried red blood cell technology designed to offer a proper method to extend the shelf-life of blood. The company provides a powder for applications in disaster relief situations, battlefield settings, and remote rural emergency rescue situations, enabling medical practitioners to have blood for transfusions in case of limited supply and in places where it is difficult to store due to the limited availability of refrigeration.
- Sector
- Healthcare
- HQ
- Louisville, KY, United States
- Founded
- 2017
- Employees
- 9
- Website
- desicorpinc.com/
- Ownership
- Privately Held (backing)
DesiCorp doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DesiCorp shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DesiCorp in its N-PORT filings yet. We sweep new filings monthly.